European Medicines Agency (EMA)
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom
Tel: 44-0-20-7523-7600
Website: http://www.ema.europa.eu/ema/
Email: info@ema.europa.eu
850 articles about European Medicines Agency (EMA)
-
European Medicines Agency Recommends Approval Of Roche's Gazyvaro For Chronic Lymphocytic Leukaemia
5/23/2014
-
TxCell Release: Col-Treg Granted Advanced Therapy Medicinal Product (ATMP) Classification By The European Medicines Agency
5/22/2014
-
MorphoSys AG's MOR208 Program To Receive Orphan Drug Designation From FDA And European Medicines Agency For The Treatment Of CLL/SLL
5/20/2014
-
Enanta Pharmaceuticals, Inc. Announces Submission Of EU Marketing Authorization Applications To European Medicines Agency For All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450
5/8/2014
-
Salix Pharmaceuticals, Ltd. And Progenics Pharmaceuticals, Inc. Announce The Acceptance Of Submission To Expand The Use Of RELISTOR In Chronic Non-Cancer Pain By European Medicines Agency
4/22/2014
-
FDA-European Medicines Agency Leadership To Discuss Pharmacovigilance At DIA Annual Meeting
4/14/2014
-
Keryx Biopharmaceuticals Announces European Medicines Agency Validation Of Marketing Authorization Application For Zerenex™
4/2/2014
-
European Medicines Agency Validates Gilead Sciences, Inc.’s Marketing Application For Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet For Genotype 1 Chronic Hepatitis C Infection
3/28/2014
-
Shire Submits INTUNIV (Guanfacine Extended Release) Marketing Authorisation Application To European Medicines Agency
3/27/2014
-
Keryx Biopharmaceuticals Announces Submission Of A Marketing Authorization Application For Zerenex™ To The European Medicines Agency
3/10/2014
-
Advanced Accelerator Applications Receives Orphan Drug Designation From FDA And European Medicines Agency For Gallium-68 DOTATATE For Use In Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors
3/4/2014
-
European Medicines Agency Accepts Marketing Authorization Application For The Medicines Company's Oritavancin
2/27/2014
-
Cubist Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance Of Tedizolid Marketing Authorization Application For Review
2/27/2014
-
FDA-European Medicines Agency Leadership To Discuss Pharmacovigilance At Drug Information Association Annual Meeting
2/25/2014
-
XBiotech USA, Inc. And European Medicines Agency Agree On Phase III Registration Study For Treatment Of Colorectal Cancer
1/30/2014
-
Teva Pharmaceutical Industries Limited, Active Biotech AB's NERVENTRA® Fails To Win European Medicines Agency Backing; Both Companies Remain Committed To The Drug
1/24/2014
-
European Medicines Agency Accepts Marketing Authorization Application For Biovest International, Inc.’s Cancer Vaccine For Treatment Of Non-Hodgkin’s Follicular Lymphoma
1/13/2014
-
Bristol-Myers Squibb Company Release: Daclatasvir Marketing Authorization Application For Treatment Of Chronic Hepatitis C Validated For Accelerated Regulatory Review By European Medicines Agency
1/8/2014
-
European Medicines Agency Accepts Otsuka America Pharmaceutical, Inc.'s Marketing Authorisation Application (MAA) For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD)
12/27/2013
-
European Medicines Agency Postpones Decision On Teva Pharmaceutical Industries Limited's MS Pill Laquinimod
12/23/2013